Brokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PT at $42.60

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $42.60.

A number of analysts recently weighed in on the stock. Piper Sandler reaffirmed a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 11th. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Finally, HC Wainwright raised their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, September 5th.

Institutional Investors Weigh In On Collegium Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the business. nVerses Capital LLC increased its stake in Collegium Pharmaceutical by 1,600.0% in the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 1,600 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Collegium Pharmaceutical by 124.5% in the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after acquiring an additional 792 shares in the last quarter. CWM LLC raised its holdings in shares of Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after acquiring an additional 736 shares during the period. TD Private Client Wealth LLC lifted its position in shares of Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after acquiring an additional 483 shares in the last quarter. Finally, Virtus Fund Advisers LLC acquired a new position in Collegium Pharmaceutical in the 3rd quarter worth approximately $72,000.

Collegium Pharmaceutical Price Performance

Shares of COLL opened at $29.70 on Thursday. Collegium Pharmaceutical has a 12 month low of $28.97 and a 12 month high of $42.29. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The stock has a fifty day moving average price of $32.48 and a 200 day moving average price of $34.30. The company has a market cap of $957.83 million, a P/E ratio of 12.80 and a beta of 0.80.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.